Xia Ming, Liu Di, Liu Haiyang, Zhao Juanyong, Tang Chengyuan, Chen Guochun, Liu Yu, Liu Hong
Hunan Key Laboratory of Kidney Disease and Blood Purification, Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, China.
Front Med (Lausanne). 2021 Dec 15;8:794962. doi: 10.3389/fmed.2021.794962. eCollection 2021.
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease and poses a global major public health burden. The preparation of Hook F (TwHF) is widely applied for treating patients with Immunoglobulin A nephropathy in China, while the molecular mechanisms remain unclear. This study aimed to verify the therapeutic mechanism of TwHF on IgAN by undertaking a holistic network pharmacology strategy in combination with and experiments. TwHF active ingredients and their targets were obtained the Traditional Chinese Medicine Systems Pharmacology Database. The collection of IgAN-related target genes was collected from GeneCards and OMIM. TwHF-IgAN common targets were integrated and visualized by Cytoscape. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to determine the predominant molecular mechanisms and pathways of TwHF on the treatment of IgAN. The protein-protein interaction network was constructed by the STRING online search tool, and hub genes were identified using R software. The expression of hub gene and related signaling were evaluated in TwHF-treated mice through immunohistochemistry and western blot and further validated in human mesangial cells (HMCs). In addition, Cell counting kit 8 (CCK8) and flow cytometry were used to detect the effects of TwHF on cell proliferation and cell cycle of mesangial cells. A total of 51 active ingredients were screened from TwHF and 61 overlapping targets related to IgAN were considered potential therapeutic targets, GO functions and KEGG analyses demonstrated that these genes were primarily associated with DNA-binding transcription factor binding, lipid and atherosclerosis pathway. Genes with higher degrees including are hub genes of TwHF against IgAN. Verification of hub gene JUN both and showed that TwHF significantly attenuated JUN phosphorylation in the kidneys of IgAN mice and aIgA1-activated HMCs, meanwhile suppressing HMCs proliferation and arresting G1-S cell cycle progression. Our research strengthened the mechanisms of TwHF in treating IgAN, inhibition of JUN activation may play a pivotal role in TwHF in alleviating IgAN renal injury.
免疫球蛋白A肾病(IgAN)是最常见的原发性肾小球疾病,给全球带来了重大的公共卫生负担。在中国,雷公藤制剂(TwHF)被广泛应用于治疗免疫球蛋白A肾病患者,但其分子机制仍不清楚。本研究旨在通过采用整体网络药理学策略并结合实验来验证TwHF对IgAN的治疗机制。通过中药系统药理学数据库获得TwHF活性成分及其靶点。从GeneCards和OMIM收集IgAN相关靶基因。通过Cytoscape整合并可视化TwHF-IgAN共同靶点。进行基因本体(GO)和京都基因与基因组百科全书(KEGG)分析,以确定TwHF治疗IgAN的主要分子机制和途径。通过STRING在线搜索工具构建蛋白质-蛋白质相互作用网络,并使用R软件鉴定枢纽基因。通过免疫组织化学和蛋白质印迹法评估TwHF处理小鼠中枢纽基因和相关信号的表达,并在人系膜细胞(HMCs)中进一步验证。此外,使用细胞计数试剂盒8(CCK8)和流式细胞术检测TwHF对系膜细胞增殖和细胞周期的影响。从TwHF中筛选出总共51种活性成分,61个与IgAN相关的重叠靶点被认为是潜在的治疗靶点,GO功能和KEGG分析表明这些基因主要与DNA结合转录因子结合、脂质和动脉粥样硬化途径相关。包括等在内的具有较高度数的基因是TwHF抗IgAN的枢纽基因。对枢纽基因JUN的体内和体外验证均表明,TwHF显著减弱IgAN小鼠肾脏和aIgA1激活的HMCs中JUN的磷酸化,同时抑制HMCs增殖并阻止G1-S细胞周期进程。我们的研究强化了TwHF治疗IgAN的机制,抑制JUN激活可能在TwHF减轻IgAN肾损伤中起关键作用。